MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1α mRNA through Decreasing Nuclear–Cytoplasmic Translocation of RNA-Binding Protein HuR
Authors:
- 1 July 2013
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 12 (7) , 1202-1212
Abstract
Microtubule inhibitors have been shown to inhibit hypoxia-inducible factor-1α (HIF-1α) expression through inhibition translation or enhancing protein degradation. Little is known of the effect of microtubule inhibitors on the stability of HIF-1α mRNA. We recently discovered a novel indoline–sulfonamide compound, 7-aryl-indoline-1-benzene-sulfonamide (MPT0B098), as a potent microtubule inhibitor through binding to the colchicine-binding site of tubulin. MPT0B098 is active against the growth of various human cancer cells, including chemoresistant cells with IC50 values ranging from 70 to 150 nmol/L. However, normal cells, such as human umbilical vein endothelial cells (HUVEC), exhibit less susceptibility to the inhibitory effect of MPT0B098 with IC50 of 510 nmol/L. Similar to typical microtubule inhibitors, MPT0B098 arrests cells in the G2–M phase and subsequently induces cell apoptosis. In addition, MPT0B098 effectively suppresses VEGF-induced cell migration and capillary-like tube formation of HUVECs. Distinguished from other microtubule inhibitors, MPT0B098 not only inhibited the expression levels of HIF-1α protein but also destabilized HIF-1α mRNA. The mechanism of causing unstable of HIF-1α mRNA by MPT0B098 is through decreasing RNA-binding protein, HuR, translocation from the nucleus to the cytoplasm. Notably, MPT0B098 effectively suppresses tumor growth and microvessel density of tumor specimens in vivo. Taken together, our results provide a novel mechanism of inhibiting HIF-1α of a microtubule inhibitor MPT0B098. MPT0B098 is a promising anticancer drug candidate with potential for the treatment of human malignancies. Mol Cancer Ther; 12(7); 1202–12. ©2013 AACR.Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- The RNA-binding Protein HuR Stabilizes Cytosolic Phospholipase A2α mRNA under Interleukin-1β Treatment in Non-small Cell Lung Cancer A549 CellsJournal of Biological Chemistry, 2011
- Differential Sensitivity of Hypoxia Inducible Factor Hydroxylation Sites to Hypoxia and Hydroxylase InhibitorsJournal of Biological Chemistry, 2011
- Microtubule disruption targets HIF-1α mRNA to cytoplasmic P-bodies for translational repressionJournal of Cell Biology, 2011
- RNA‐binding proteins implicated in the hypoxic responseJournal of Cellular and Molecular Medicine, 2009
- Antivascular Actions of Microtubule-Binding DrugsClinical Cancer Research, 2009
- Nuclear HuR accumulation through phosphorylation by Cdk1Genes & Development, 2008
- Hypoxia-mediated Selective mRNA Translation by an Internal Ribosome Entry Site-independent MechanismJournal of Biological Chemistry, 2008
- Protein Kinase Cα-dependent Phosphorylation of the mRNA-stabilizing Factor HuR: Implications for Posttranscriptional Regulation of Cyclooxygenase-2Molecular Biology of the Cell, 2007
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- HuR and mRNA stabilityCellular and Molecular Life Sciences, 2001